A Prospective, Open-label, Non-comparative Study To Assess The Safety, Tolerability And Efficacy Of Voriconazole For The Primary And Salvage Treatment Of Invasive Candidiasis, Candidemia, And Esophageal Candidiasis In Pediatric Subjects

Trial Profile

A Prospective, Open-label, Non-comparative Study To Assess The Safety, Tolerability And Efficacy Of Voriconazole For The Primary And Salvage Treatment Of Invasive Candidiasis, Candidemia, And Esophageal Candidiasis In Pediatric Subjects

Discontinued
Phase of Trial: Phase III

Latest Information Update: 07 Mar 2017

At a glance

  • Drugs Voriconazole (Primary)
  • Indications Candidiasis
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 15 Sep 2016 Results (n=53) assessing safety and efficacy outcomes of Voriconzaole in pediatric patients from NCT01092832 and NCT00836875 studies, published in the Pediatric Infectious Disease Journal.
    • 19 Jan 2015 New trial record
    • 18 Oct 2010 According to ClinicalTrial.gov record, status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top